Clinical trial No longer in our active list Interventional Ages 18 to 36

Using myo-inositol to improve fertility in women with PCOS

Official title: Myo-Inositol as an Adjuvant to Letrozole for Infertility in PolyCystic Ovary Syndrome (MALI-PCOS): a Randomized Pilot Trial

Run by University of Oklahoma · NCT04407754 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing if adding myo-inositol to a fertility medication can help women with PCOS ovulate and get pregnant.

More Polycystic Ovary Syndrome trials

Quick facts

Study typeInterventional
Ages18 Years to 36 Years
SexAll
Enrollment168 (estimated)
SponsorUniversity of Oklahoma
Academic / other
Locations1 site (Oklahoma City, Oklahoma)
Trial IDNCT04407754 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women aged 18-36 with a desire for pregnancy and diagnosed with oligo- or anovulation due to PCOS.

Probably not a fit

Patients with infertility due to causes other than PCOS or those with uncontrolled thyroid dysfunction may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of myo-inositol combined with letrozole for inducing ovulation in women diagnosed with polycystic ovary syndrome (PCOS). It is a double-blind, randomized study where participants will receive either a placebo or a blend of myo-inositol and D-chiro inositol alongside letrozole for up to five treatment cycles or until pregnancy is achieved. Participants will undergo various assessments, including metabolic parameter analysis and quality of life questionnaires, to evaluate the treatment's impact. The study aims to provide insights into the potential benefits of inositol supplementation in enhancing fertility outcomes for women with PCOS.

Why it matters

Potential benefit: If successful, this study could improve ovulation rates and fertility outcomes for women with PCOS.

How similar studies have gone: Previous studies have shown promising results with inositol supplementation in improving metabolic and reproductive outcomes in women with PCOS, suggesting this approach is supported by existing evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female patient age 18-36
* Desire for pregnancy
* Diagnosis of oligo- or anovulation secondary to polycystic ovary syndrome -All subjects must have ovulatory dysfunction and at least one of the remaining two criteria:hyperandrogenism or polycystic ovarian morphology on ultrasound
* At least one patent fallopian tube
* Normal uterine cavity
* Male partner with sperm concentration of at least 14 million/mL in at least one ejaculate.

Exclusion Criteria:

* Cause of anovulation other than PCOS such as uncontrolled thyroid dysfunction or hyperprolactinemia
* Presence of another major infertility factor
* Diabetes
* Contraindication to pregnancy
* Myo-inositol use \< 3 months prior to study enrollment
* Concomitant metformin use. Previous use is allowed with last use at least 6 weeks prior to randomization.

Where it's running

  • OUHSC Reproductive Medicine Clinic
    Oklahoma City, Oklahoma, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.